HOUSTON, TX / ACCESSWIRE / April 12, 2019 / The U.S. FDA could provide a substantial boost to cannabis stocks in coming weeks.

On May 31, 2019, the government agency will hold its first public hearing on legalizing CBD in food and drinks, to figure out how to regulate such products.

"The goal of the hearing is to obtain additional scientific data and other information related to cannabis and cannabis-derived compounds, both from botanical and synthetic sources, to inform our regulatory oversight of these products," the agency has noted. "FDA does not intend for this hearing to produce any decisions or new positions on specific regulatory questions, but this hearing is expected to be an important step in our continued evaluation of cannabis and cannabis-derived compounds in FDA-regulated products."

Any positive outcome is likely to be a big catalyst for related stocks, including Blissco Cannabis Corp. (CSE: BLIS)(OTCQB: HSTRF), Tilray Inc. (NASDAQ: TLRY), and HEXO Corporation (NYSE: HEXO)(TO: HEXO).

Blissco Cannabis Corp. (BLIS) (HSTRF) just announced that its products are now available for purchase online in British Colombia at BC Cannabis Stores, and are available for wholesale purchase by provincially licensed private retailers through the BC Liquor Distribution Branch's (BCLDB) cannabis wholesale portal. In addition, Blissco is pleased to share that it has shipped its second order to the LDB.

This new order contains both whole flower and pre-rolled products that include strains, such as CBD AC/DC, Green Cush, and Cold Creek Kush.

"Blissco is gaining significant momentum with regards to revenue, and we are delighted to have Blissco's premium cannabis products for sale in our home province. We will also soon be shipping products to Alberta, New Brunswick and Saskatchewan as per our supply and distribution agreements in those provinces," said Damian Kettlewell, Blissco CEO.

For More Information on Blissco Cannabis Corp., Click Here.

Tilray Inc. (TLRY) partnered with Anheuser-Busch InBev in a $100 million deal to research cannabis-infused drinks for the Canadian market. Each company will invest $50 million in the project to study non-alcoholic drinks containing CBD, or cannabidiol.

"We are delighted to be joining forces with a world-leading beverage company, AB InBev, to research how to create enjoyable cannabis beverage products," said Brendan Kennedy, Tilray CEO. "Tilray and AB InBev share a commitment to responsible product development and marketing, and we look forward to beginning our work on this important partnership as Tilray continues to pioneer the development of a professional, transparent, and well-regulated cannabis industry."

For More Information on Tilray Inc., Click Here.

HEXO Corporation (HEXO) is currently working with Molson Coors to create non-alcoholic, cannabis-infused drinks. "Canada is breaking new ground in the cannabis sector and, as one of the country's leading beverage companies, Molson Coors Canada has a unique opportunity to participate in this exciting and rapidly expanding consumer segment," said Frederic Landtmeters, president and CEO of Molson Coors Canada.

For More Information on HEXO Corporation, Click Here.

MarijuanaStox.com is a leading web destination for all cannabis related companies. Investors can also find current marijuana-related quality financial, medical, legal and social news.

MarijuanaStox.com is a media agency in North America dedicated to the cannabis industry, helping companies that operate in the space to attract quality investors, working capital and real publicity. Since 2005, we have had public companies in the US and Canada have rely on us to grow and succeed.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media which has a partnership with www.MarijuanaStox.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.

Story continues